Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project
Touchlight secures government grant to support its £14m investment in scale-up DNA manufacturing
Touchlight announces first FDA clearance of an IND utilising doggybone DNA
FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy utilising doggybone DNA
Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform
Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Lonza and Touchlight collaborate on end-to-end mRNA offering
Touchlight awarded ILAP for therapeutic DNA vaccine
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Touchlight and Versameb announce GMP manufacturing supply agreement
mRNA-based therapeutics summit
Join us at the mRNA-based therapeutics summit in Boston, US (July 26-28, 2023).
Our team will be available to discuss your advanced therapy manufacturing. Learn how our enzymatically produced DNA vector called doggybone DNA (dbDNA) can significantly improve speed to manufacture, safety and scalability in comparison to plasmid DNA, for vaccine development.